The Albanese Government has effectively rejected or obfuscated most of the committee's recommendations, but that does not mean the response has no value or cannot contribute to positive change. Stakeholders must understand the nuance and recognise the real opportunities because these processes never deliver the 'magic bullet'.
A minimalist but entirely predictable response - the opportunities are in the nuance
December 1, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News
